Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
 |
2022 –2029 |
 |
USD 3,426.71 Million |
 |
USD 6,295.77 Million |
 |
% |
|
|
Global Soft Tissue Sarcoma Market, By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The global soft tissue sarcoma market is expected to witness significant growth during the forecast period. Sarcomas account for less than 1.0% of all adult cancers. Over 65% of the major drugs have been developed or are being developed for administration through the oral route. Particularly, around 60% of the soft tissue sarcoma targeting therapeutics have been developed for use as the 1st line of treatment.
Data Bridge Market Research analyses a growth rate in the global soft tissue sarcoma market in the forecast period 2022-2029. The expected CAGR of global soft tissue sarcoma market is tend to be around 7.9% in the mentioned forecast period. The market was valued at USD 3426.71 million in 2021, and it would grow upto USD 6295.77 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Liposarcoma is a type of soft tissue sarcoma wherein cancer originates from the fat cells in soft tissue present in the skin's middle and outer layers. It is caused either by genetic factor, radiation treatment or maybe others idiopathic reasons. Liposarcoma can be of four types: myxoid liposarcoma, pleomorphic liposarcoma, well-differentiated liposarcoma, and dedifferentiated liposarcoma. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Drivers
According to the WHO 2016, liposarcoma is the most common type of sarcomas and is classified as a rare disease, accounting for about 17-20% of all sarcoma cases. According to the report published by the Genetics Education Center, University of Kansas Medical Center, about 15% of all the cancers have an inherited susceptibility and almost 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. This boost the market growth.
Heavy unmet needs within the market present a main opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the rest in Phase I and Pre-clinical trials. The probable role for use of immuno-oncology agents in sarcomas is presently under evaluation in Phase I/II clinical trials. Thus, all these initiatives increase the market growth.
Opportunities
Around 80% of the reported deals were established in the past three years, with the majority being reported in 2020. The maximum of the instances were licensing agreements (45%). Additionally, more than 50% of the agreements were signed for therapeutics targeting liposarcoma. Thus, all these partnerships create much opportunities for the market growth.
For more than 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. Although, even after complete surgical resection, around 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The establishment of targeted therapy has revolutionized the treatment model for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a crucial role in the growth of the market during the forecast period.
Awareness among patients as well as healthcare providers about the incidence of liposarcoma is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This creates more opportunity in the market.
Restraints/Challenges
There are various side-effects associated with the soft tissue sarcoma drugs. Effects such as swelling under the skin, tummy, mouth sores, fatigue, nausea that highly disrupts the treatment market.
The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market. Increasing cost for the radiotherapy and chemotherapy may hamper the growth of soft tissue sarcoma treatment market during the forecast period.
This global soft tissue sarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global soft tissue sarcoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The global soft tissue sarcoma market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
Route of Administration
End-Users
Distribution Channel
The global soft tissue sarcoma market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global soft tissue sarcoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the increase awareness about the diseases and rapidly disposable income.
North America dominates the market due to the increase prevalence of soft tissue sarcoma, high demand of targeted therapies and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global soft tissue sarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global soft tissue sarcoma market
Key players operating in the global soft tissue sarcoma market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
The market is segmented based on , By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029. .
The Global Soft Tissue Sarcoma Market size was valued at USD 3426.71 USD Million in 2021.
The Global Soft Tissue Sarcoma Market is projected to grow at a CAGR of 7.9% during the forecast period of 2022 to 2029.
The major players operating in the market include F. Hoffmann-La Roche Ltd. , Mylan N.V. , Teva Pharmaceutical Industries Ltd. , Sanofi , Pfizer Inc. , GSK plc , Novartis AG , Bayer AG , Lilly , Merck &, Co.Inc. , Sun Pharmaceutical Industries Ltd. , Aurobindo Pharma , Lupin , Dr. Reddy',s Laboratories Ltd , Endo International plc .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
